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The 4th revised World Health Organization (WHO) classifi-
cation of tumors of the central nervous system (CNS) highlights 
the importance of integrated diagnosis of CNS tumors [1]. In 
addition to histological features, molecular signatures are now 
mandatory for diagnosis, as well as patient management in neu-
ro-oncological aspects. Molecularly different tumors could have 
different biological behavior and treatment response to thera-
peutic agents. The 2016 update of WHO classification suggests 
well-established molecular parameters in diagnostic algorithms 
of diffuse gliomas. For appropriate integrated diagnosis of diffuse 
gliomas, one needs to examine the isocitrate dehydrogenase 
(IDH) mutation and 1p/19q status. In this study, we investigated 
current adjuvant examination being performed in Korea for diag-
nosis of brain tumors.
MATERIALS AND METHODS
The survey was distributed to the members of the Korean 
Society of Neuropathology (n = 12) from May to June 2017 (30 
days). We expected that most institutions would have prepared 
for the new diagnostic criteria proposed by the revised WHO 
classification. 
Survey questionnaires included the number of neuropatholog-
ical specimens per year, ancillary tests being performed for brain 
tumor diagnosis, and the type of methods for the ancillary tests. 
The results were analyzed after receiving answers to the survey. 
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by the Institutional Review Board of Gachon University Gil Medi-
cal Center with a waiver of informed consent (GFIRB2018-266).
RESULTS
The survey questions were answered by 10 of the 12 neuro-
pathologists who received the survey questionnaires. All 10 re-
spondents were neuropathologists working in tertiary centers 
capable of neurosurgery and neuropathological diagnosis. The 
total number of neuropathological cases for a year, including tu-
mor, non-tumor, muscle, and peripheral nerve biopsy, was more 
than 300 cases in five centers (average, 906; range, 392 to 1,900), 
200–300 cases in one center, 100–200 cases in another, 50–100 
in two, and less than 50 cases in two others. All 10 centers make 
the diagnosis based on the 4th revised 2016 WHO classifica-
tion. 
Immunohistochemical stainings in gliomas 
For diagnosis of astrocytic and oligodendroglial tumors, immu-
nohistochemistry (IHC) for glial fibrillary acidic protein (GFAP), 
oligodendrocyte transcription factor 2 (OLIG2), α-thalassemia/
mental retardation syndrome X-linked (ATRX), IDH1, BRAF 
(VE1), Ki-67, p53, S-100, vimentin, epidermal growth factor re-
ceptor (EGFR), synaptophysin, H3.3K27M, and H3.3K27me3 
was used. Depending on the centers, three to 11 markers were 
used for diagnosis. The most commonly used IHC markers were 
IDH1, ATRX, p53, and Ki-67 (Fig. 1A).
In pilocytic astrocytomas and pleomorphic xanthoastocyto-
mas (PXAs), most IHC markers were overlapped with the items 
mentioned above (Supplementary Fig. S1).
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Fig. 2. Current methods for isocitrate dehydrogenase (IDH) mutation test (A) and 1p/19q status (B) among respondents. PNA, peptide nu-
cleic acid; NGS, next-generation sequencing; FISH, fluorescence in situ hybridization; PCR, polymerase chain reaction; LOH, loss of hetero-
zygosity.
Fig. 1. Immunohistochemistry markers used in glioma (A) and ep-
endymoma (B). Alphabet A–J represents respondents. IDH1, isoci-
trate dehydrogenase 1; ATRX, α-thalassemia/mental retardation 
syndrome X-linked; GFAP, glial fibrillary acidic protein; EGFR, epi-
dermal growth factor receptor; OLIG2, oligodendrocyte transcrip-
tion factor 2; EMA, epithelial membrane antigen.
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antigen, Ki-67, and p53 were most frequently used, followed by 
CD99 and OLIG2 (Fig. 1B).
Molecular testing in gliomas
Regarding astrocytic and oligodendroglial tumors, IDH mu-
tation tests (including IDH1 and IDH2) (n = 9) and 1p/19q loss 
of heterozygosity (LOH) (n = 10) were performed before mak-
ing a final diagnosis. Next-generation sequencing (NGS) (n = 4), 
pyrosequencing (n = 3), peptide nucleic acid (PNA) clamping 
method (n = 3), and Sanger sequencing (n = 1) methods were 
used for IDH mutation testing (Fig. 2A). One center performs 
both NGS and PNA clamping methods for IDH mutation test 
whereas the other one uses only IDH1 IHC. While most of the 
centers used fluorescence in situ hybridization (FISH) to evalu-
ate the 1p/19q status, two centers conducted NGS in addition 
to FISH, for evaluating the 1p/19q status. One center used poly-
merase chain reaction–based LOH analysis (Fig. 2B)
Additional molecular testing included MGMT (O6-methyl-
guanine–DNA methyltransferase) methylation test (n = 8), and 
telomerase reverse transcriptase (TERT) promoter mutation (n = 
8; four single test, four NGS). BRAF mutation test and NGS test, 
for V600E, were performed in eight centers. One center sepa-
rately performed BRAF mutation test in all astrocytic and oli-
godendroglial tumors. Two centers performed BRAF mutation 
test in all infiltrating gliomas except oligodendroglioma.
For pilocytic astrocytomas and PXAs, most molecular testings 
were overlapped with the items mentioned above (Supplementary 
Fig. S2).
For ependymomas, three centers performed NGS and one 
center performed an additional FISH test for 1q gain. 
Ganglioglioma and dysembryoplastic neuroepithelial tumor 
Regarding glioneuronal tumors, the survey focused on gangli-
oglioma and dysembryoplastic neuroepithelial tumor (DNET), 
as they comprised the majority of glioneuronal tumors. In cases 
of ganglioglioma, the most commonly used IHC markers were 
GFAP, Ki-67, and synaptophysin, followed by NeuN and 
CD34 (Fig. 3A), whereas for DNET, synaptophysin, GFAP, Ki-
67, CD34, and NeuN were the most commonly used (Fig. 3B). 
Regarding molecular testing, one center performed the same 
molecular tests as in gliomas. In some centers, IDH mutation 
test (n = 3 in ganglioglioma, n = 2 in DNET), BRAF V600E 
test (n = 1 in ganglioglioma, n = 2 in DNET), and MGMT meth-
ylation test (n = 2 in ganglioglioma, n=3 in DNET) were per-
formed. NGS was performed for ganglioglioma in three centers 
and DNET in one. Five centers did not perform further molec-
ular testing in ganglioglioma and DNET. 
Embryonal tumors
p53 (n = 9), Ki-67 (n = 9), and synaptophysin (n=8) were the 
most commonly used IHC markers in medulloblastoma, fol-
lowed by GFAP. For molecular classification, surrogate IHC 
markers, including growth factor receptor bound protein 2-as-
sociated protein 1 (GAB1; n = 5), β-catenin (n = 1), filamin A (n = 
4), and yes-associated protein 1 (YAP1) (n = 4), were used. All 
10 centers performed integrase interactor 1 IHC for atypical 
teratoid rhabdoid tumors and one center performed additional 
BRG2 IHC. LIN28A IHC was used for embryonal tumors in 
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Fig. 3. Immunohistochemistry markers used in ganglioglioma (A) 
and dysembryoplastic neuroepithelial tumor (B). Alphabet A–J rep-
resents respondents. GFAP, glial fibrillary acidic protein; IDH1, iso-
citrate dehydrogenase 1; OLIG2, oligodendrocyte transcription 
factor 2; ATRX, α-thalassemia/mental retardation syndrome X-
linked.
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Meningioma
All 10 centers performed Ki-67 IHC for meningioma, and 
additional phosphohistone H3 IHC was used in six centers. 
Three centers separately examined the TERT promoter muta-
tion. Two centers performed NGS for meningioma, which in-
cluded TERT in NGS panel. 
DISCUSSION
We conducted surveys in 10 pathology labs in tertiary cen-
ters in Korea to investigate the current status of adjunctive ex-
amination for CNS tumor diagnosis. The 4th revised 2016 WHO 
classification adopted layered diagnosis encompassing histologi-
cal and molecular features, which can precisely classify CNS tu-
mors, thus allowing for more accurate predictions, regarding 
treatment response and prognosis [1]. In particular, IDH muta-
tion and 1p/19q status are the most important diagnostic dis-
criminators of astrocytic and oligodendroglial tumors.
We found that the majority of tertiary centers examined IDH 
mutation and 1p/19q status before development of final diag-
nosis in glial tumors. Particularly, IDH1 IHC is included in 
routine IHC panel in most centers and appears to be a very help-
ful surrogate marker for IDH mutation, because approximately 
over 90% of IDH mutation is IDH1 [2]. Although ATRX is not 
essential in diagnosis of glial tumors based on the current WHO 
classification, 80% of respondents routinely used ATRX IHC.
The ATRX gene is a telomere maintenance-related gene that 
functions in chromatic remodeling and maintains genomic sta-
bility incorporating H3.3 histone proteins into telomeres [3,4]. 
ATRX gene inactivation is correlated with the alternative length-
ening of telomeres. A subset of gliomas harboring ATRX mu-
tation is characterized by IDH mutation and 1p/19q intact [5-
7]. Loss of nuclear expression by IHC is a highly sensitive and 
specific feature of ATRX alteration [4] and can be used as a sur-
rogate marker for ATRX mutation. Combining IHC panel with 
IDH1 and ATRX helps to predict astrocytic tumors in cases of 
those lacking ATRX expression [8]. 
MGMT methylation and TERT promoter mutation are not 
required for diagnosis, but impact patient prognosis and treat-
ment response [9-11]. Promoter methylation of MGMT induc-
es epigenetic silencing of the MGMT gene, restoring alkylated 
DNA. Temozolomide is an alkylating agent used in glioblasto-
ma and the benefits of temozolomide treatment have been 
shown in patients with MGMT methylation [10]. TERT pro-
moter mutation increases telomerase activity and is frequently 
found in glioblastomas and oligodendrogliomas [12]. Previous 
study classified gliomas into molecular groups based on IDH 
mutation, 1p/19q, and TERT mutation status [9]. Results 
showed higher survival rate in TERT and IDH mutation groups 
in grade II and III gliomas, whilst single TERT mutation showed 
the worst survival rate of all gliomas [9]. MGMT methylation 
and TERT promoter mutation tests were conducted in 80% of 
the respondents, and four centers obtained TERT promoter mu-
tation results by NGS. 
NGS has been evolving rapidly and is being adopted in many 
tertiary centers in Korea. NGS uses targeted gene panels to ana-
lyze hundreds of genes. In Korea, there are essential genes such 
as HER2, EGFR, ALK, KRAS, NRAS, BRAF, BRCA1, 
BRCA2, KIT, PDGFRA, IDH1, IDH2, MYC (C-myc), and N-
myc (MYCN) for non-hereditary solid tumors, that should be 
included in said panels. Most tertiary centers running NGS use 
gene panels with 50–300 genes. For gliomas, only one of the 
respondents was using a separate neuropathology gene panel, 
and the remaining were using a common panel for solid tumors. 
For infiltrating gliomas, NGS was routinely performed in six 
centers. In addition to EGFR, BRAF, IDH1, and IDH2 which 
are essential panel genes, six respondents had TERT, TP53, and 
SMARCB1 also in their panels, and one institution substituted 
FISH with 1p/19q LOH (by evaluation of microsatellite loci) 
by NGS.
For the diagnosis of glioneuronal tumors, CD34 and synap-
tophysin IHC were the most commonly performed assays. Syn-
aptophysin is a marker for presynaptic vesicle, and is widely 
used to detect neuron or neuronal differentiation. DNET and 
ganglioglioma are the most common glioneuronal tumors and 
the differential diagnosis between these two is important, because 
DNET is a benign tumor but ganglioglioma could undergo 
malignant transformation [13,14]. Expression of CD34 is the 
one characteristic feature that favors ganglioglioma diagnosis 
over DNET [13]. BRAF V600E mutation could be found vari-
ably in glioneuronal tumors including DNET, ganglioglioma, 
and PXA [15,16] and could be used as a diagnostic and targe-
table marker. 
For meningioma, all respondents performed Ki-67 IHC rou-
tinely. Although Ki-67 labeling index (LI) is not included in 
the current grading system, Ki-67 LI is correlated with mitosis 
and tumor recurrence [17,18]. In previous studies, tumors with 
more than 3% proliferative index, showed a shorter recurrence 
time after resection [19]. TERT mutation also has been reported 
in meningiomas, especially in recurrent and high grade (grades 
II and III) tumors [20]. Although an overall incidence of TERT 
mutation is low (around 5%) in meningioma, TERT mutation 
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predicted more aggressive behavior and poor prognosis in me-
ningioma [21,22]. 
Medulloblastoma is one of the most common embryonal tu-
mors and the second most common CNS tumor in children. 
Medulloblastoma is considered a heterogeneous group that can 
be classified into four molecular subgroups based on Sonic 
hedgehog (SHH) and WNT status. In daily practice, using three 
(GAB1, filamin A, and YAP1) or four IHC (GAB1, filamin A, 
YAP1, and β-catenin) panel could discriminate SHH, WNT, 
and non-SHH/WNT subgroups [23]. Moreover, TP53 muta-
tion can designate the WNT type, IHC of p53 in mutant pat-
tern could help to limitedly predict the molecular subtype [24]. 
Five respondents (50%) used GAB1 and four used a panel com-
posed of GAB1, filamin A, and YAP1, and nine respondents 
used Ki-67 and p53 as routine IHC panel in medulloblastoma. 
NGS can evaluate clinically significant variants across hun-
dreds of targeted genes. In Korea, CNS tumor is classified un-
der non-genetic solid tumor category. Among the essentially 
required 14 genes, EGFR, BRAF, IDH1, and IDH2 are relevant 
to CNS tumors. In the present survey, almost all tertiary centers 
except one used commercial panels and platforms from the 
same manufacturers, which also meets the government’s mini-
mum requirements. NGS is an accurate and sensitive tool for 
detection of additional genetic alteration with much less amount 
of DNA or RNA compared to the conventional techniques, 
which require more amount of tissue and only detect one altera-
tion in one test. However, in daily practice, NGS is still an expen-
sive ancillary test as it has a 2–4 week-turnaround time. For 
prompt diagnosis and subsequent proper treatment, IDH muta-
tion and 1p/19q LOH are being examined separately to achieve 
more rapid final diagnosis. 
In conclusion, we found that most tertiary centers handling 
neuropathological specimens were making diagnosis according 
to the 2016 WHO classification. However, a limitation is still 
present because present survey could not encompass every single 
pathology lab in Korea. Although most CNS tumors in Korea 
are expected to be managed in tertiary centers that participated 
in this survey, there is a possibility that some cases that are not 
handled in tertiary centers may not be properly examined for 
the basic molecular status such as IDH mutation. For the sake of 
proper diagnosis, the first line of ancillary tests composed of IHC 
and simple molecular tests should be established. The second line 
of ancillary tests should encompass NGS assay and other further 
tests that can cover the detailed analysis of CNS tumors. 
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Supplementary Fig. S1. Immunohistochemistry markers used in pilocytic astrocytoma (A) and pleomorphic xanthoastrocytoma (B). Alpha-
bet A–J represents respondents. GFAP, glial fibrillary acidic protein; ATRX, α-thalassemia/mental retardation syndrome X-linked; IDH1, isoci-
trate dehydrogenase 1; OLIG2, oligodendrocyte transcription factor 2; EGFR, epidermal growth factor receptor.
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Supplementary Fig. S2. Molecular markers used in pilocytic astrocytoma (A) and pleomorphic xanthoastrocytoma (B). Alphabet A–J repre-
sents respondents. IDH1, isocitrate dehydrogenase 1; MGMT, O6-methylguanine–DNA methyltransferase; IDH2, isocitrate dehydrogenase 2; 
NGS, next-generation sequencing; TERT, telomerase reverse transcriptase.
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